DesignPreclinical immunometabolism study combining human PBMC-tumor co-culture experiments with a BALB/c AB1-Gag murine mesothelioma challenge model and macrophage-depletion experiments.
PopulationHealthy-donor human peripheral blood mononuclear cells in vitro and 8- to 10-week-old BALB/c mice with subcutaneous AB1-Gag mesothelioma tumors; no treated human cancer patients.
SampleMouse treatment groups used approximately n=5 per group in the reported tumor-challenge and macrophage-depletion experiments; cell experiments used small replicate sets.
InterventionHigh-dose NMN. In the mouse tumor model, NMN 300 mg/kg was administered intraperitoneally from tumor inoculation and twice weekly through day 14; comparator anti-PD-1 was 200 mg/kg. Human PBMC co-cultures used NMN concentrations up to 10 mM.
EndpointsTumor growth by size and luminescence; Tumor and splenic immune-cell composition; M1-like versus M2-like tumor-associated macrophage phenotype; Macrophage cytokine and activation markers; Effect of macrophage depletion on NMN-associated tumor control; NAD+ salvage-pathway enzyme expression in human PBMC co-cultures
What the publication reported
This study investigated whether high-dose NMN could alter anti-tumor immune responses. The researchers first tested human immune cells in tumor-cell co-culture, then used a mouse mesothelioma model.
In mice, high-dose NMN slowed tumor growth to a degree reported as comparable with anti-PD-1 in this specific model. Unlike anti-PD-1, NMN did not mainly act through tumor-specific T cells. Instead, tumor-associated macrophages shifted toward an inflammatory M1-like phenotype, and depleting macrophages reduced the NMN-associated tumor-control effect.
The work is mechanistic and preclinical. It does not establish NMN as a cancer treatment, does not show benefit in human cancer patients, and does not establish safety alongside cancer therapy.
Key findings
NMN altered expression of NAD+ salvage-pathway enzymes in human PBMCs co-cultured with tumor cells.
In the AB1 mesothelioma mouse model, high-dose NMN reduced tumor progression relative to untreated controls.
NMN increased inflammatory M1-like tumor-associated macrophages and decreased M2-like macrophages.
Macrophage depletion substantially weakened the tumor-control effect seen with NMN, supporting macrophage involvement.
NMN increased macrophage activation/cytokine markers including TNF-α, IL-12β, CD38, and IFN-γ in reported experiments.
NMN did not reproduce the anti-PD-1-associated increase in tumor-specific CD8 T-cell responses.
What it cannot establish
The anti-tumor findings were obtained in a mouse mesothelioma model, not in cancer patients.
The NMN regimen was a high-dose intraperitoneal experimental treatment and does not represent routine oral supplementation.
Group sizes were small and the study was a brief report rather than a clinical efficacy trial.
The model used an engineered AB1-Gag tumor system, which may not generalize to other cancers or human tumor microenvironments.
One author is an employee and shareholder of GeneHarbor, and the work included collaborative research support from GeneHarbor.
The study does not establish whether NMN could help, harm, or interact with standard cancer therapies in humans.
HealthspanX claim boundary: This study does not establish NMN as a cancer therapy, prove benefit in human tumors, establish safety during chemotherapy or immunotherapy, or support routine NMN use in people with cancer.
